I'm LongbridgeAI, I can summarize articles.CF PharmTech Inc. (HK:2652) announced a discounted H-share placing of approximately HK$300 million. The company will issue 21,747,700 new shares at HK$13.82 each, representing a ~12% discount to recent market prices. This transaction dilutes existing holdings by about 5.30%. Gross proceeds are expected to be HK$300.55 million, with net proceeds around HK$294.81 million, subject to standard completion conditions.
CF PharmTech. Inc. Class H ( (HK:2652) ) has shared an announcement.
CF PharmTech, Inc. has agreed to place 21,747,700 new H shares through a syndicate of placing agents under its existing general mandate. The shares, each with a nominal value of RMB1.00, represent about 7.23% of its H shares in issue and about 5.30% of total shares before the transaction, modestly diluting existing holders.
The placing price is set at HK$13.82 per H share, reflecting discounts of around 12% to both the last closing price and the recent five‑day average. Assuming full placement, CF PharmTech expects gross proceeds of about HK$300.55 million and net proceeds of approximately HK$294.81 million, with completion still subject to conditions, prompting a cautionary note to shareholders and potential investors.
More about CF PharmTech. Inc. Class H
CF PharmTech, Inc. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2652. The company issues H shares to international investors via the Hong Kong Stock Exchange, using capital markets to support its pharmaceutical operations and growth strategy.
Average Trading Volume: 603,238
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$6.45B
Find detailed analytics on 2652 stock on TipRanks’ Stock Analysis page.